AKE Stock Analysis: Arkema | PA
Specialty Chemicals | PA, France | Market Cap: 4.209m EUR | 12M Return: 10.1% | FR0010313833 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.3M
EPS Trend: -91.4%
Qual. Beats: 0
Rev. Trend: -82.8%
Qual. Beats: -1
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Arkema S.A. is a French specialty materials manufacturer operating through three business segments: Adhesive Solutions, Advanced Materials and Coating Solutions, and Intermediates. The company supplies industrial customers across construction, automotive, packaging, electronics, oil and gas, renewable energy, coatings, and water treatment markets, with operations spanning Europe, North America, and Asia.
Positioned within the diversified chemicals sub-industry of the Materials sector, Arkema focuses on specialty rather than commodity chemicals, serving B2B clients with high-performance polymers, performance additives, coating resins, and industrial intermediates. Incorporated in 2003 and headquartered in Puteaux, France, the company targets both established applications and emerging growth areas such as lightweighting, new energies, bio-based products, and recycling solutions.
- PVDF demand surges on electric vehicle battery adoption
- EU F-gas regulation phases down fluorogases revenue
- Bostik adhesives margin expansion lifts specialty materials earnings
| Net Income: 60.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 1.11 > 1.0 |
| NWC/Revenue: 18.41% < 20% (prev 29.58%; Δ -11.17% < -1%) |
| CFO/TA 0.06 > 3% & CFO 915.6m > Net Income 60.0m |
| Net Debt (3.18b) to EBITDA (1.16b): 2.74 < 3 |
| Current Ratio: 1.52 > 1.5 & < 3 |
| Outstanding Shares: last quarter (102.7m) vs 12m ago 35.12% < -2% |
| Gross Margin: 17.83% > 18% (prev 19.02%; Δ -1.19% > 0.5%) |
| Asset Turnover: 63.38% > 50% (prev 67.86%; Δ -4.47% > 0%) |
| Interest Coverage Ratio: 2.54 > 6 (EBIT TTM 332.8m / Interest Expense TTM 130.8m) |
| A: 0.12 (Total Current Assets 4.80b - Total Current Liabilities 3.16b) / Total Assets 14.2b |
| B: 0.30 (Retained Earnings 4.18b / Total Assets 14.2b) |
| C: 0.02 (EBIT TTM 332.8m / Avg Total Assets 14.0b) |
| D: 0.94 (Book Value of Equity 6.78b / Total Liabilities 7.21b) |
| Altman-Z'' = 2.87 = A |
| DSRI: 1.23 (Receivables 1.91b/1.65b, Revenue 8.90b/9.44b) |
| GMI: 1.07 (GM 19.02% / 17.83%) |
| AQI: 0.95 (AQ_t 0.38 / AQ_t-1 0.40) |
| SGI: 0.94 (Revenue 8.90b / 9.44b) |
| TATA: -0.06 (NI 60.0m - CFO 915.6m) / TA 14.2b) |
| Beneish M = -2.85 (Cap -4..+1) = A |
As of October 07, 2026, the stock is trading at EUR 55.10 with a total of 235,869 shares traded. Over the past week, the price has changed by -1.17%, over one month by -6.69%, over three months by -1.43% and over the past year by +10.14%.
Current recommended Stop Loss: 52.70 (which is 4.4% or 1.9 ATR below the current price).
Arkema has no consensus analysts rating.
P/E Trailing = 232.2917
P/E Forward = 10.4712
P/S = 0.4729
P/B = 0.6405
P/EG = 0.4673
Revenue TTM = 8.90b EUR
EBIT TTM = 332.8m EUR
EBITDA TTM = 1.16b EUR
Long Term Debt = 2.61b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.37b EUR (from shortTermDebt, last quarter)
Debt = 4.65b EUR (from shortLongTermDebtTotal, last quarter) + Leases 373.6m
Net Debt = 3.18b EUR (calculated: Debt 4.65b - CCE 1.47b)
Enterprise Value = 7.39b EUR (4.21b + Debt 4.65b - CCE 1.47b)
Interest Coverage Ratio = 2.54 (Ebit TTM 332.8m / Interest Expense TTM 130.8m)
EV/FCF = 19.83x (Enterprise Value 7.39b / FCF TTM 372.5m)
FCF Yield = 5.04% (FCF TTM 372.5m / Enterprise Value 7.39b)
FCF Margin = 4.18% (FCF TTM 372.5m / Revenue TTM 8.90b)
Net Margin = 0.67% (Net Income TTM 60.0m / Revenue TTM 8.90b)
Gross Margin = 17.83% ((Revenue TTM 8.90b - Cost of Revenue TTM 7.31b) / Revenue TTM)
Gross Margin QoQ = 19.99% (prev 17.60%)
Tobins Q-Ratio = 0.52 (Enterprise Value 7.39b / Total Assets 14.2b)
Interest Expense / Debt = 2.82% (Interest Expense 130.8m / Debt 4.65b)
Taxrate = 35.24% (37.6m / 106.7m)
NOPAT = 215.5m (EBIT 332.8m * (1 - 35.24%))
Current Ratio = 1.52 (Total Current Assets 4.80b / Total Current Liabilities 3.16b)
Debt / Equity = 0.69 (Debt 4.65b / totalStockholderEquity, last quarter 6.78b)
Debt / EBITDA = 2.74 (Net Debt 3.18b / EBITDA 1.16b)
Debt / FCF = 8.53 (Net Debt 3.18b / FCF TTM 372.5m)
Total Stockholder Equity = 6.55b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.43% (Net Income 60.0m / Total Assets 14.2b)
RoE = 0.92% (Net Income TTM 60.0m / Total Stockholder Equity 6.55b)
RoCE = 3.63% (EBIT 332.8m / Capital Employed (Equity 6.55b + L.T.Debt 2.61b))
RoIC = 1.81% (NOPAT 215.5m / Invested Capital 11.9b)
WACC = 4.90% (E(4.21b)/V(8.85b) * Re(8.30%) + D(4.65b)/V(8.85b) * Rd(2.82%) * (1-Tc(0.35)))
Discount Rate = 8.30% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 47.26 | Cagr: 14.94%
[DCF] Terminal Value 77.97% ; FCFF base≈307.9m ; Y1≈353.0m ; Y5≈519.5m
[DCF] Fair Price = 61.43 (EV 7.82b - Net Debt 3.18b = Equity 4.64b / Shares 75.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -91.40 | EPS CAGR: -27.96% | SUE: 0.23 | # QB: 0
Revenue Correlation: -82.77 | Revenue CAGR: -2.76% | SUE: -3.17 | # QB: -1
EPS current Quarter (2026-09-30): EPS=1.39 | Chg30d=-2.46% | Revisions=+25% | Analysts=2
EPS current Year (2026-12-31): EPS=4.41 | Chg30d=-0.23% | Revisions=+18% | GrowthEPS=+2.1% | GrowthRev=+0.7%
EPS next Year (2027-12-31): EPS=5.35 | Chg30d=-1.43% | Revisions=-18% | GrowthEPS=+21.4% | GrowthRev=+2.1%
[Analyst] Revisions Ratio: +5% (up=9, down=8)